← Eichor
Study identifier: NCT04037995 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Real World Study of End-stage Liver Disease in China

Condition: End Stage Liver DIsease · Complication  ·  Sponsor: Huashan Hospital

PhaseN/A
Planned participants10000
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The aims of this study are exploring the current situation of end-stage liver disease in China, and the optimization of diagnosis and treatment. Liver cirrhosis often accompanied by a series of complications. Therefore, it is necessary to standardize the diagnosis and treatment of liver cirrhosis and its complications. End-stage liver disease mainly refers to the late stage of liver disease caused by various chronic liver damage. Its main feature is that liver function can not meet the physiological needs of human body. This study is a single-center, prospective and observational real-world study aimed at investigating and analyzing the current diagnosis and treatment of liver cirrhosis and end-stage liver disease in China.

This description comes directly from the study's public registry record.

Talk to the study team

Jingwen Ai, Doctor  ·  13764990804  ·  JINGWENAI1990@126.COM

Always discuss trial participation with your own doctor first.

Locations (1)

HuaShan HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04037995